BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
2.120
-0.190 (-8.23%)
At close: Mar 28, 2025, 4:00 PM
2.090
-0.030 (-1.42%)
After-hours: Mar 28, 2025, 7:57 PM EDT
BioXcel Therapeutics Stock Forecast
BTAI's stock price has decreased by -95.4% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for BioXcel Therapeutics stock have an average target of 42.6, with a low estimate of 4.00 and a high estimate of 80. The average target predicts an increase of 1,909.43% from the current stock price of 2.12.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for BioXcel Therapeutics stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +2,966.04% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $48 | Strong Buy | Maintains | $80 → $48 | +2,164.15% | Jan 30, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $112 → $4 | Strong Buy → Sell | Downgrades | $112 → $4 | +88.68% | Jan 7, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $112 → $80 | Strong Buy | Maintains | $112 → $80 | +3,673.58% | Jan 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $112 → $80 | Strong Buy | Maintains | $112 → $80 | +3,673.58% | Oct 21, 2024 |
Financial Forecast
Revenue This Year
2.83M
from 1.38M
Increased by 105.36%
Revenue Next Year
4.16M
from 2.83M
Increased by 46.93%
EPS This Year
-27.20
from -98.35
EPS Next Year
-17.28
from -27.20
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 5.6M | 7.4M | 26.3M | |||
| Avg | 2.8M | 4.2M | 15.5M | |||
| Low | 2.0M | 1.5M | 4.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 308.6% | 159.4% | 530.4% | |||
| Avg | 105.4% | 46.9% | 271.9% | |||
| Low | 42.0% | -48.1% | 13.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -24.86 | -8.23 | -7.92 | |||
| Avg | -27.20 | -17.28 | -11.17 | |||
| Low | -33.41 | -29.20 | -15.78 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.